August 27, 2020

Q&A with Industry Leaders


Q&As with industry leaders, from Bioprocess Development Forum

Steven Lynn, Executive Vice-President, Pharmaceuticals, Regulatory Compliance Associates

Peter Guterstam, PhD, Product Manager of Next Generation Resins & Technologies at Cytiva

Peggy Lio, Senior Director of Global Cell Culture Services at Cytiva

Dr. Tobias Hahn, co-founder and CEO of GoSilico

Dr. Oliver Hardick, Business Leader in the BioProcess group at Cytiva

Rita Peters, Editorial Director of BioPharm International   

Dr. Mats Lundgren, Customer Applications Director at Cytiva

Eric Langer, President and Managing Partner at BioPlan Associates 

Neil Goss, Research and Development at CSL BioPlasma, Australia, and co-author of Production of Plasma Proteins for Therapeutic Use

Rita Peters, Editorial Director of BioPharm International  

Günter Jagschies, Strategic Customer Relations Leader, Cytiva

Aaron Noyes, Head of Downstream Processing at Codiak BioSciences 

John Curling, 3rd BioProcessing Asia Conference chair 

Jonathan Royce, Business Leader for Chromatography Resins, Cytiva

Andrew Sinclair, President and Founder of BioPharm Services

Greg Bolton, Scientific Director, Amgen

Rita Peters, Editorial Director of BioPharm International 

Konstantin Konstantinov, VP Late Stage Process Development, Genzyme

Rita Peters, Editorial Director of BioPharm International  

Parrish Galliher, Chief Technology Officer Upstream at Cytiva

Eric Langer, President and Managing Partner at BioPlan Associates

Phil Lester, Co-Organizer of the HTPD Conference

Dr. Anurag Rathore, Professor, Department of Chemical Engineering, Indian Institute of Technology, Delhi (Part 1)

Dr. Anurag Rathore, Professor, Department of Chemical Engineering, Indian Institute of Technology, Delhi (Part 2)

Dr. Arne Staby, Fellow, Novo Nordisk

Dr. Karol Lacki, Customer Collaborations Leader, Cytiva

Professor Alois Jungbauer, Department of Biotechnology, BOKU

Günter Jagschies, Cytiva

Jeff Carter, Cytiva

Rita Peters, Editorial Director of BioPharm International 

Eric Langer, BioPlan Associates

Tags: process development; bioprocess development; Q&A